600812.SH
华北制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.61
−6.11%Year over year
Reported trailing growth
- Revenue
- -10.8%
- EBITDA
- —
- EBIT
- -11.0%
- EPS
- -3.5%
- Free cash flow
- +452.2%
- Operating cash flow
- +41.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.2%
- EBITDA
- +101.3%
- EBIT
- +50.4%
- Net income
- +511.8%
- EPS
- +497.2%
- Free cash flow
- +11.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026